The Canadian Agency for Drugs and Technologies in Health (CADTH) has launched the CADTH Pharmaceutical Reviews Update. This is a new consolidated publication that will communicate updates to CADTH’s drug review process. It replaces previous individual publications, including CDR Update, pCODR Update, Therapeutic Review Update, and Updates for Patient Groups. In this first issue of the CADTH Pharmaceutical Reviews Update, among other announcements, CADTH invites stakeholder comments on a number of proposals, and announces changes to the Pan-Canadian Oncology Drug Review.
Related Publications & Articles
-
Health Canada and the Competition Bureau commit to information sharing to combat false, misleading or deceptive health claims
On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework of cooperat...Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Generic Submissions Under Review list will identify generic filers
On February 23, 2024, Health Canada announced that it will expand the information available on the Generic Submissions Under Review (GSUR) list.Read More